Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 244

1.

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.

Xu T, Wu H, Jin S, Min H, Zhang Z, Shu Y, Wen W, Guo R.

Medicine (Baltimore). 2017 Aug;96(33):e7732. doi: 10.1097/MD.0000000000007732.

2.

Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.

Rambau P, Kelemen LE, Steed H, Quan ML, Ghatage P, Köbel M.

Int J Mol Sci. 2017 Feb 27;18(3). pii: E515. doi: 10.3390/ijms18030515.

3.

A novel clinicopathological analysis of early stage ovarian Sertoli-Leydig cell tumors at a single institution.

Nam SM, Kim JW, Eoh KJ, Kim HM, Lee JY, Nam EJ, Kim S, Kim SW, Kim YT.

Obstet Gynecol Sci. 2017 Jan;60(1):39-45. doi: 10.5468/ogs.2017.60.1.39. Epub 2017 Jan 19.

4.

Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.

Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.

J Ovarian Res. 2017 Feb 10;10(1):9. doi: 10.1186/s13048-017-0304-9.

5.

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).

Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X.

J Ovarian Res. 2017 Jan 25;10(1):7. doi: 10.1186/s13048-016-0300-5.

7.

Anticancer Efficacy of Polyphenols and Their Combinations.

Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M.

Nutrients. 2016 Sep 9;8(9). pii: E552. doi: 10.3390/nu8090552. Review.

8.

Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer.

Fruscio R, Ceppi L, Corso S, Galli F, Dell'Anna T, Dell'Orto F, Giuliani D, Garbi A, Chiari S, Mangioni C, Milani R, Floriani I, Colombo N, Bonazzi CM.

Br J Cancer. 2016 Sep 6;115(6):641-8. doi: 10.1038/bjc.2016.254. Epub 2016 Aug 18.

9.
10.

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C.

J Clin Oncol. 2016 Jul 1;34(19):2279-86. doi: 10.1200/JCO.2015.65.8153. Epub 2016 May 23.

11.

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.

Schlappe BA, Mueller JJ, Zivanovic O, Gardner GJ, Long Roche K, Sonoda Y, Chi DS, O'Cearbhaill RE.

Gynecol Oncol. 2016 Jul;142(1):13-18. doi: 10.1016/j.ygyno.2016.05.015. Epub 2016 May 21.

12.

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.

Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H, Kozasa K, Hashimoto K, Sawada K, Kimura T.

PLoS One. 2016 Mar 17;11(3):e0151050. doi: 10.1371/journal.pone.0151050. eCollection 2016.

13.

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.

Yasukawa M, Fujihara H, Fujimori H, Kawaguchi K, Yamada H, Nakayama R, Yamamoto N, Kishi Y, Hamada Y, Masutani M.

Int J Mol Sci. 2016 Feb 24;17(3):272. doi: 10.3390/ijms17030272.

14.

Relevance of frozen sections and serum markers in invasive squamous cell carcinoma arising from ovarian mature cystic teratoma: two case reports.

Tazo Y, Yoshimura Y, Shoda T, Kyushima N, Okada T, Yamazaki H.

J Med Case Rep. 2016 Jan 22;10:20. doi: 10.1186/s13256-015-0783-5.

15.

A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report.

Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Nishikawa T, Tanaka J, Tanaka T, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Kazama S, Ishihara S, Sunami E, Watanabe T.

J Med Case Rep. 2016 Jan 19;10:14. doi: 10.1186/s13256-016-0799-5.

16.

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C.

Int J Gynecol Cancer. 2016 Feb;26(2):255-60. doi: 10.1097/IGC.0000000000000591.

17.

ARID1A gene mutation in ovarian and endometrial cancers (Review).

Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D.

Oncol Rep. 2016 Feb;35(2):607-13. doi: 10.3892/or.2015.4421. Epub 2015 Nov 16. Review.

18.

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK.

Mol Cancer Ther. 2015 Dec;14(12):2677-86. doi: 10.1158/1535-7163.MCT-14-0630. Epub 2015 Oct 29.

19.

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA.

Ann Oncol. 2016 Jan;27(1):114-21. doi: 10.1093/annonc/mdv500. Epub 2015 Oct 20.

20.

Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.

Katagiri H, Nakayama K, Razia S, Nakamura K, Sato E, Ishibashi T, Ishikawa M, Iida K, Ishikawa N, Otsuki Y, Nakayama S, Kyo S.

Int J Oncol. 2015 Dec;47(6):2037-44. doi: 10.3892/ijo.2015.3191. Epub 2015 Oct 6.

Supplemental Content

Loading ...
Support Center